- Home
- IMUX vs MIST Comparison
IMUX vs MIST Comparison
Compare IMUX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | MIST |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Canada |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.2M | 95.3M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMUX | MIST |
|---|---|---|
| Price | $7.91 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $43.09 | $5.57 |
| AVG Volume (30 Days) | 330.0K | ★ 900.2K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $125.44 |
| Revenue Next Year | N/A | $462.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.63 |
| 52 Week High | $17.43 | $3.06 |
Technical Indicators
Market Signals| Indicator | IMUX | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 48.45 |
| Support Level | $6.35 | $0.75 |
| Resistance Level | $8.60 | $1.42 |
| Average True Range (ATR) | 0.57 | 0.06 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 61.97 | 62.55 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.